Springworks Therapeutics Inc (SWTX)
$43.07 -3.45 (-7.42%)Market Cap | 3.31B |
Revenue (ttm) | 191.59M |
Net Income (ttm) | -258.13M |
EPS (ttm) | N/A |
PE Ratio | 0.00 |
Forward PE | N/A |
Profit Margin | -134.73% |
Debt to Equity Ratio | 0.00 |
Volume | 1,784,600 |
Avg Vol | 2,526,018 |
Day's Range | N/A - N/A |
Shares Out | 74.94M |
Stochastic %K | 5% |
Beta | 0.75 |
Analysts | Strong Sell |
Price Target | $72.88 |
Latest News on SWTX


Mar 11, 2025, 9:15 AM EDT - 23 days ago
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

Feb 20, 2025, 6:30 AM EST - 6 weeks ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 19, 2025, 8:00 AM EST - 6 weeks ago
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

Feb 17, 2025, 4:05 PM EST - 6 weeks ago
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics

Feb 11, 2025, 8:20 PM EST - 7 weeks ago
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Feb 11, 2025, 5:27 PM EST - 7 weeks ago
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Jan 30, 2025, 7:00 AM EST - 2 months ago
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025


Jan 13, 2025, 5:56 AM EST - 2 months ago
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Jan 3, 2025, 6:30 AM EST - 3 months ago
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 8:30 AM EST - 3 months ago
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Dec 15, 2024, 2:00 PM EST - 3 months ago
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Nov 26, 2024, 7:00 AM EST - 4 months ago
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:20 PM EST - 5 months ago
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 9:25 AM EST - 5 months ago
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 12, 2024, 6:30 AM EST - 5 months ago
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 11, 2024, 7:00 AM EST - 5 months ago
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting



Nov 5, 2024, 7:00 AM EST - 5 months ago
SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Oct 22, 2024, 7:00 AM EDT - 5 months ago
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Aug 28, 2024, 6:30 AM EDT - 7 months ago
FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

Aug 9, 2024, 9:09 AM EDT - 8 months ago
SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)

Aug 7, 2024, 5:46 PM EDT - 8 months ago
SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 7, 2024, 1:08 PM EDT - 8 months ago
SpringWorks Therapeutics, Inc. (SWTX) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 6:30 AM EDT - 8 months ago
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 29, 2024, 6:30 AM EDT - 8 months ago
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

Jul 23, 2024, 7:00 AM EDT - 9 months ago
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Jul 2, 2024, 12:49 PM EDT - 9 months ago
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm

Jul 1, 2024, 6:30 AM EDT - 9 months ago
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Jun 5, 2024, 7:00 AM EDT - 10 months ago
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024, 5:13 PM EDT - 11 months ago
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 8, 2024, 7:00 AM EDT - 11 months ago
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

May 5, 2024, 2:22 AM EDT - 11 months ago
SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript

May 2, 2024, 6:30 AM EDT - 1 year ago
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Apr 24, 2024, 1:31 PM EDT - 1 year ago
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 18, 2024, 7:00 AM EDT - 1 year ago
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024



Feb 27, 2024, 6:30 AM EST - 1 year ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Feb 22, 2024, 7:00 AM EST - 1 year ago
SpringWorks Therapeutics to Present at Upcoming Investor Conferences

Jan 31, 2024, 7:00 AM EST - 1 year ago
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 6:30 AM EST - 1 year ago
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 21, 2023, 7:00 AM EST - 1 year ago
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
